The FDA for the first time is facing pharma-backed criticism of its new practice of publicly releasing partially redacted drug rejection letters. The law firm

Sanofi CEO Paul Hudson bet big on immunology. When Belén Garijo takes over as CEO next week, she will have to decide whether to continue

RIPK1 is becoming a relative desert for large drugmakers. Eli Lilly has joined the exodus, ripping apart the remainder of its up to $960 million

The first recipients of the UK government’s £500 million Sovereign AI fund have been announced, including two life sciences-focused startups.

The first recipients of the UK government’s £500 million Sovereign AI fund have been announced, including two life sciences-focused start-ups.